Adherium Limited
Adherium Limited
Your view on ADR.AX
Overview
What the company does, where it operates, and who runs it.
About Adherium Limited
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Dawn Bitz
- Headquarters
- 447 Collins Street, Melbourne, VIC, AU
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Dawn Bitz
- Headquarters
- 447 Collins Street, Melbourne, VIC, AU
Adherium Limited specializes in developing, manufacturing, and providing advanced digital health solutions. The company's core mission is to enhance medication adherence for individuals managing chronic conditions in key international markets, spanning New Zealand, Australia, Europe, North America, and Asia. A central offering is Hailie, a comprehensive system engineered to optimize medication use for patients suffering from chronic respiratory illnesses like asthma and chronic obstructive pulmonary disease (COPD). This innovative solution integrates Bluetooth-enabled Hailie sensors, which discreetly attach to patients' inhalers to deliver immediate feedback. The Hailie ecosystem is further supported by an intuitive mobile application and a dedicated online portal. Established in 2001, Adherium Limited is headquartered in Auckland, New Zealand.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Adherium Limited, and the rating behind it. ADR.AX last traded at AUD 0.10; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Adherium Limited. Starting points for Adherium Limited: EPS -AUD 0.97, beta 1.05 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Adherium Limited. Adherium Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Adherium Limited. Trailing twelve-month EPS for Adherium Limited stands at -AUD 0.97. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Adherium Limited. Adherium Limited has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Adherium Limited valued side by side against its closest peers. Adherium Limited is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Adherium Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Adherium Limited executives and directors. Shares of Adherium Limited have traded between AUD 0.10 and AUD 0.67 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Adherium Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Adherium Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Adherium Limited. Coverage tracks Adherium Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.